
July 10 (Reuters) - Soleno Therapeutics Inc SLNO.O:
SOLENO THERAPEUTICS ANNOUNCES PRELIMINARY FINANCIAL AND OPERATIONAL RESULTS FOR THE SECOND QUARTER ENDED JUNE 30, 2025
SOLENO THERAPEUTICS: EXPECTS NET REVENUE FROM SALES OF VYKAT(TM) XR, FOR THREE MONTHS ENDED JUNE TO BE BETWEEN $31.0 MILLION - $33.0 MILLION